New drug combo takes aim at Hard-to-Treat cancers
NCT ID NCT04443088
First seen Mar 21, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and check for side effects. About 78 participants will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Horizon Oncology Research, LLC,
COMPLETEDLafayette, Indiana, 47905, United States
-
START
COMPLETEDSan Antonio, Texas, 78229, United States
-
UT Health
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INV-1120 (an experimental oral drug) and pembrolizumab (an immunotherapy)
What this could lead to
If this early trial shows safety and hints of tumor shrinkage, it could point toward a new treatment option for advanced cancers like colorectal, breast, or lung cancer.
What could go wrong
This is a very early Phase 1 study with only 78 participants. The drug may not be safe or effective at the doses tested, and side effects are unknown. Success is far from guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.